Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 4, 2011, Pages 749-757

  Kadivar, Mustakhusen H ^a   Sinha, Praveen Kumar ^a   Kushwah, Dharmendra ^a   Jana, Pijush ^a   Sharma, Hitesh ^a   Bapodra, Atul ^b  

^a Unimark Remedies Ltd   (India)

^b SAURASHTRA UNIVERSITY   (India)

Author keywords

Carry over study; Febuxostat; Impurity profile; LC MS MS

Indexed keywords

AMIDE; FEBUXOSTAT;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG IMPURITY; ELECTROSPRAY MASS SPECTROMETRY; INFRARED SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS; MASS SPECTROMETER; MASS SPECTROMETRY; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; GOUT SUPPRESSANTS; HUMANS; TANDEM MASS SPECTROMETRY; THIAZOLES;

EID: 84860391360     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.07.039     Document Type: Article

References (10)

1. Stamp L.K., O'Donnell J.L. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J. 2007, 37:258-266.
2. Michael A., Becker H., Ralph Schumacher, Wortmann Robert L. Febuxostat a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum. 2005, 52:916-923.
3. Okamoto K., Eger B.T., Nishino T., Kondo S., Pai E.F., Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. J. Biol. Chem. 2003, 278:1848-1855.
4. Zhao L., Takano Y., Horiuchi H. Effect of Febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism pathway. Arthritis Rheum. 2003, 48:S531.
5. Horiuchi H., Ota M., Kobayashi M., Kaneko H., Kasahara Y., Nishimura S., et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res. Commun. Mol. Pathol. Pharmacol. 1999, 104:307-319.
6. Ye Q., Huang Y., Rusowicz A. Org. Process. Res. Dev. 2010, 14:238-241.
7. Vasanti S., et al. Impurity profile - a review. Drug Invention Today 2009, 1:81-88.
8. ICH Q3A(R) International Conference of Harmonization 2002, IFMPA, Geneva.
9. ICH Q3B(R) International Conference of Harmonization 2002, IFMPA, Geneva.
10. Silverstein R.M., Webster F.X. Spectroscopic Identification of Organic Compounds 2007, Wiley-India, New Delhi. sixth ed.